Simulation des essais cliniques dans le développement des médicaments
Thérapie, 59 3 (2004) 287-295
Publié en ligne : 2007-03-01
Article cité par
La fonctionnalité Article cité par… liste les citations d'un article. Ces citations proviennent de la base de données des articles de EDP Sciences, ainsi que des bases de données d'autres éditeurs participant au programme CrossRef Cited-by Linking Program. Vous pouvez définir une alerte courriel pour être prévenu de la parution d'un nouvel article citant " cet article (voir sur la page du résumé de l'article le menu à droite).
Article cité :
Citations de cet article :
Computer Simulation for Effective Pharmaceutical Kinetics and Dynamics: A Review
Gaurav Tiwari, Anuja Shukla, Anju Singh and Ruchi TiwariCurrent Computer-Aided Drug Design 20 (4) 325 (2024)
https://doi.org/10.2174/1573409919666230228104901
Methods to Develop an in silico Clinical Trial: Computational Head-to-Head Comparison of Lisdexamfetamine and Methylphenidate
José Ramón Gutiérrez-Casares, Javier Quintero, Guillem Jorba, Valentin Junet, Vicente Martínez, Tamara Pozo-Rubio, Baldomero Oliva, Xavier Daura, José Manuel Mas and Carmen MontotoFrontiers in Psychiatry 12 (2021)
https://doi.org/10.3389/fpsyt.2021.741170
Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer
Jinani Jayasekera, Yisheng Li, Clyde B Schechter, et al.JNCI: Journal of the National Cancer Institute 110 (12) 1360 (2018)
https://doi.org/10.1093/jnci/djy059
Impact of disease, drug and patient adherence on the effectiveness of antiviral therapy in pediatric HIV
Chiara Piana, Meindert Danhof and Oscar Della PasquaExpert Opinion on Drug Metabolism & Toxicology 13 (5) 497 (2017)
https://doi.org/10.1080/17425255.2017.1277203
Pharmacodynamic Modelling of Biomarker Data in Oncology
Robert C. JacksonISRN Pharmacology 2012 1 (2012)
https://doi.org/10.5402/2012/590626
Model‐based design of rituximab dosage optimization in follicular non‐Hodgkin's lymphoma
David Ternant, Guillaume Cartron, Emilie Hénin, Michel Tod, Pascal Girard and Gilles PaintaudBritish Journal of Clinical Pharmacology 73 (4) 597 (2012)
https://doi.org/10.1111/j.1365-2125.2011.04125.x
A Matrix to Determine Health Economic Viability Throughout Product Development: A Pharmaceutical Industry Perspective
Michiel Hemels, Michael Wolden and Thomas R. EinarsonDrug Information Journal 43 (6) 749 (2009)
https://doi.org/10.1177/009286150904300612
Are Population Pharmacokinetic and/or Pharmacodynamic Models Adequately Evaluated?
Karl Brendel, C??line Dartois, Emmanuelle Comets, et al.Clinical Pharmacokinetics 46 (3) 221 (2007)
https://doi.org/10.2165/00003088-200746030-00003
Validation by simulation of a clinical trial model using the standardized mean and variance criteria
Ismail Abbas, Joan Rovira and Josep CasanovasJournal of Biomedical Informatics 39 (6) 687 (2006)
https://doi.org/10.1016/j.jbi.2005.12.005
Dose Finding in Drug Development
Nick HolfordStatistics for Biology and Health, Dose Finding in Drug Development 73 (2006)
https://doi.org/10.1007/0-387-33706-7_6
Modélisation et essais cliniques en pédiatrie
Philippe Jacqmin, Nathalie Labouret, François Gueyffier, et al.Therapies 60 (4) 379 (2005)
https://doi.org/10.2515/therapie:2005055
Modélisation numérique et simulation : nouvelles applications en pharmacologie
Jean-Pierre Boissel, Michel Cucherat, Patrice Nony, et al.Therapies 60 (1) 1 (2005)
https://doi.org/10.2515/therapie:2005001
Modelling and Clinical Trials in Paediatrics
Philippe Jacqmin, Nathalie Labouret, François Gueyffier, et al.Therapies 60 (4) 385 (2005)
https://doi.org/10.2515/therapie:2005056